OncoMatch/Clinical Trials/NCT05320588
A Study in Patients With Advanced Cancers
Is NCT05320588 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BIO-106 and Pembrolizumab for advanced cancer.
Treatment: BIO-106 · Pembrolizumab — A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Impaired cardiac function or history of clinically significant cardiac disease [excluded]
Impaired cardiac function or history of clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology Austin · Austin, Texas
- University of Texas MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify